Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Interest Expenses (2016 - 2017)

Capricor Therapeutics (CAPR) has 7 years of Interest Expenses data on record, last reported at $80307.0 in Q4 2017.

  • For Q4 2017, Interest Expenses fell 21.96% year-over-year to $80307.0; the TTM value through Sep 2018 reached $80307.0, down 80.94%, while the annual FY2017 figure was $398807.0, 15.71% up from the prior year.
  • Interest Expenses reached $80307.0 in Q4 2017 per CAPR's latest filing, down from $107653.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $107653.0 in Q3 2017 and bottomed at $3711.0 in Q1 2013.
  • Average Interest Expenses over 5 years is $62536.8, with a median of $61681.0 recorded in 2015.
  • Peak YoY movement for Interest Expenses: crashed 99.51% in 2013, then soared 780.76% in 2014.
  • A 5-year view of Interest Expenses shows it stood at $24859.0 in 2013, then surged by 142.9% to $60383.0 in 2014, then increased by 5.3% to $63583.0 in 2015, then surged by 61.84% to $102905.0 in 2016, then dropped by 21.96% to $80307.0 in 2017.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $80307.0 in Q4 2017, $107653.0 in Q3 2017, and $105527.0 in Q2 2017.